YWT alleviates AKI by suppressing apoptosis-related proteins such as Caspase-3, Caspase-9, and BAX, enhancing Bcl-2 expression, increasing the LC3 II/I ratio, and reducing p62, a marker of autophagy.<h4>Discussion and conclusion</h4>This study confirms the therapeutic efficacy of YWT in cisplatin-induced AKI, potentially linked to its ability to inhibit apoptosis, activate autophagy, and mitigate mitochondrial damage. The gene discussed is CASP3; the disease is acute kidney injury.